首页> 外国专利> ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD

ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD

机译:人血淋巴细胞的分离糖蛋白IB多肽,融合蛋白,DNA分子(版本),表达载体(版本),细胞(版本),多肽表达方法,融合蛋白表达方法,药物结合方法(骨架)生物系统中的细胞对生物组织的抑制作用,生物系统中蛋白质与生物组织的结合抑制方法及疾病处理方法

摘要

FIELD: chemistry; biochemistry.;SUBSTANCE: invention relates to biotechnology and specifically to obtaining versions of glycoprotein IV alpha polypeptide of human thrombocytes (GPIbalpha) and can be used in medicine to treat vascular disorders. Using a recombinant technique, a polypeptide is obtained, which contains substitutes in SEQ ID NO:2 selected from: Y276F K237V C65S; K237V C65S; Y276F C65S; or Y276F Y278F Y279F K237V C65S. The obtained polypeptide is used to inhibit bonding of leucocytes to biological tissue or for treating disorders associated with activation of thrombocytes.;EFFECT: invention enables to obtain GPIbalpha polypeptide which bonds with von Willebrand factor with affinity which is at least 10 times higher than in natural GPIbα polypeptide, and also has low affinity for bonding with alpha-thrombin, lower aggregation and/or high resistance to proteolysis relative the polypeptide with SEQ ID NO:2.;41 cl, 3 dwg, 8 ex
机译:领域:化学;生物化学;本发明涉及生物技术,尤其涉及获得人血小板细胞糖蛋白IVα多肽(GPIbα)的形式,并且可以用于治疗血管疾病。使用重组技术,获得了一种多肽,该多肽在SEQ ID NO:2中包含选自Y276F K237V C65S的替代物; K237V C65S; Y276F C65S;或Y276F Y278F Y279F K237V C65S。获得的多肽用于抑制白细胞与生物组织的结合或用于治疗与血小板激活相关的疾病。 GPIbα多肽,并且相对于具有SEQ ID NO:2的多肽,与α-凝血酶的结合亲和力低,聚集度低和/或对蛋白水解的抵抗力高; 41 cl,3 dwg,8 ex

著录项

  • 公开/公告号RU2403262C2

    专利类型

  • 公开/公告日2010-11-10

    原文格式PDF

  • 申请/专利权人 UAJT;

    申请/专利号RU20060100306

  • 申请日2004-06-14

  • 分类号C07K14/755;C12N15/12;C12N15/62;C12N1;C12N5;C12N15/63;C12P21/02;A61K38/37;A61P7/02;

  • 国家 RU

  • 入库时间 2022-08-21 18:29:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号